title: Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation based on Compression UltraSonography (DACUS) study.
abstract: Residual vein thrombosis (RVT) indicates a prothrombotic state and is useful for evaluating the optimal duration of oral anticoagulant treatment (OAT). Patients with a first episode of deep vein thrombosis, treated with OAT for 3 months, were managed according to RVT findings. Those with RVT were randomized to either stop or continue anticoagulants for 9 additional months, whereas in those without RVT, OAT was stopped. Outcomes were recurrent venous thromboembolism and/or major bleeding. Residual thrombosis was detected in 180 (69.8%) of 258 patients; recurrent events occurred in 27.2% of those who discontinued (25/92; 15.2% person-years) and 19.3% of those who continued OAT (17/88; 10.1% person-years). The relative adjusted hazard ratio (HR) was 1.58 (95% confidence interval [CI], 0.85-2.93; P = .145). Of the 78 (30.2%) patients without RVT, only 1 (1.3%; 0.63% person-years) had a recurrence. The adjusted HR of patients with RVT versus those without was 24.9 (95% CI, 3.4-183.6; P = .002). One major bleeding event (1.1%; 0.53% person-years) occurred in patients who stopped and 2 occurred (2.3%; 1.1% person-years) in those who continued OAT. Absence of RVT identifies a group of patients at very low risk for recurrent thrombosis who can safely stop OAT. This trial was registered at http://www.ClinicalTrials.gov as no. NCT00438230.
authors.affiliation: Cattedra ed Unità di Ematologia con trapianto, Dipartimento di Medicina Interna, Malattie Cardiovascolari e Nefrourologiche, Università degli Studi di Palermo, Italy. sergio.siragusa@unipa.it
authors.forename: Sergio
authors.initials: S
authors.lastname: Siragusa
authors.forename: Alessandra
authors.initials: A
authors.lastname: Malato
authors.forename: Raffaela
authors.initials: R
authors.lastname: Anastasio
authors.forename: Valeria
authors.initials: V
authors.lastname: Cigna
authors.forename: Glauco
authors.initials: G
authors.lastname: Milio
authors.forename: Corrado
authors.initials: C
authors.lastname: Amato
authors.forename: Mario
authors.initials: M
authors.lastname: Bellisi
authors.forename: Maria Teresa
authors.initials: MT
authors.lastname: Attanzio
authors.forename: Oreste
authors.initials: O
authors.lastname: Cormaci
authors.forename: Massimo
authors.initials: M
authors.lastname: Pellegrino
authors.forename: Alberto
authors.initials: A
authors.lastname: Dolce
authors.forename: Alessandra
authors.initials: A
authors.lastname: Casuccio
authors.forename: Guido
authors.initials: G
authors.lastname: Bajardi
authors.forename: Guglielmo
authors.initials: G
authors.lastname: Mariani
mesh_terms: D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D055502:Secondary Prevention; D016896:Treatment Outcome; D014463:Ultrasonography; D020246:Venous Thrombosis / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy*
chemical_list: D000925:Anticoagulants